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Over recent years, interest in the use of autologous 
T-cells as a therapeutic strategy for cancer has increased 
substantially. Studies using ex vivo expanded tumor-
infiltrating lymphocytes (TILs) demonstrated that adoptive 
T-cell therapy could achieve dramatic reductions in 
tumor burden (1). However such an approach is limited 
to those patients from whom tumor-specific T-cells 
can be isolated. Genetic engineering bestows tumor-
specificity into an otherwise polyclonal T-cell population 
through engraftment of a new T-cell receptor (TCR), or 
a chimeric antigen receptor (CAR). As a result, T-cells 
from any patient can theoretically be re-directed against 
a chosen antigen on malignant cells, thus broadening the 
application of adoptive T-cell therapy. However, a key 
hurdle in the widespread use of adoptive T-cell therapy is 
the paucity of antigens exclusively expressed by tumors. 
In a recent article published in Cell, Roybal et al. (2) have 
detailed a novel CAR-based ‘antigen recognition circuit’ 
that aims to overcome this hurdle by uncoupling efficient 
tumor eradication from the ‘on-target, off tumor’ toxicity 
associated with concomitant targeting of healthy tissue.
CARs are genetically delivered fusion proteins, in which 
an extracellular antigen recognition domain is coupled 
to a bespoke signaling endodomain. Antigen ligation 
mediates endodomain oligomerization, resulting in T-cell 
activation and subsequent target cell lysis. Recently, CAR 
T-cells targeting the ubiquitous B-cell antigen, CD19, have 
demonstrated dramatic results in the treatment of B-cell 
acute lymphoblastic leukemia (B-ALL), with complete 
response rates between 70–90% observed in multiple 
treatment refractory patients (3-5). These results are 
unprecedented in early phase drug development and have 
generated a great excitement with regards to the use of CAR 
T-cell therapy in the wider context of cancer treatment. 
Unfortunately, many tumor-associated antigens (TAA) are 
also endogenously expressed in healthy cells, resulting in 
the potential for acute toxicity. In certain circumstances 
this ‘on-target, off tumor’ toxicity is considered acceptable, 
such as the concomitant B-cell aplasia observed during 
CD19 CAR T-cell trials. However, in other scenarios, 
unintentional targeting of healthy tissue can mediate 
unacceptable, or even life threatening, toxicity (6,7). 
To overcome the potentially toxic constraints of 
targeting a single TAA, strategies that enable selective 
tumor targeting through recognition of antigen patterns 
are of great interest. One emerging approach is to engineer 
CAR T-cells to have dual specificity, whereby two receptors 
targeting distinct TAA are co-expressed in the T-cell. 
Each receptor provides a distinct signal that in isolation is 
insufficient to mediate T-cell activation. When combined, 
however, these signals synergize, thus stimulating a T-cell 
response. The utility of these so-called ‘AND gates’ is 
predicated on the exclusive expression of defined antigen 
combinations by tumors. By engineering the T-cells to 
respond solely to this antigenic pattern, selective tumor 
targeting may be achieved, whilst sparing healthy cells that 
express either of the targeted antigens in isolation. 
Initial proof-of-concept studies investigating the 
feasibility of such an AND gate strategy took advantage 
of the signaling requirements of CAR T-cells. Due to 
poor co-stimulatory molecule expression by tumors, a co-
stimulatory signaling motif is often incorporated into the 
Editorial
Gated chimeric antigen receptor T-cells: the next logical step in 
reducing toxicity?
David Marc Davies1, John Maher1,2
1Department of Research Oncology, King’s Health Partners Integrated Cancer Centre, Guy’s Hospital Campus, King’s College London, London 
SE1 9RT, UK; 2Department of Clinical Immunology and Allergy, King’s College Hospital NHS Foundation Trust, London SE5 9RS, UK 
Correspondence to: Dr. John Maher. Department of Research Oncology, Guy’s Hospital, Great Maze Pond, London SE1 9RT, UK. 
Email: john.maher@kcl.ac.uk.
Submitted May 01, 2016. Accepted for publication May 10, 2016.
doi: 10.21037/tcr.2016.06.04
View this article at: http://dx.doi.org/10.21037/tcr.2016.06.04
S62 Davies and Maher. Using logic gates to reduce toxicity of CAR T-cells
© Translational Cancer Research. All rights reserved. Transl Cancer Res 2016;5(S1):S61-S65 tcr.amegroups.com
CAR endodomain to improve function. These ‘second 
generation’ CARs are able to mediate significantly more 
robust T-cell proliferation and better T-cell persistence in 
patients than first generation CARs, which incorporate only 
an activating signal (8,9). Whilst second generation CARs 
provide this co-stimulation in cis, efficient co-stimulation 
can also be achieved in trans, through expression of a 
separate co-stimulatory receptor (10). 
Based on these observations, Wilkie et al. co-expressed a 
first generation CAR targeting ErbB2 with a chimeric co-
stimulatory receptor (CCR), though which CD28 signaling 
was delivered upon engagement of tumor-associated 
MUC-1 (11). These CAR/CCR T-cells demonstrated 
significantly better proliferation on ErbB2+ MUC-1+ tumor 
cells as compared to tumours expressing either MUC-1 or 
ErbB2. This demonstrated that both signal 1 (CAR) and 
signal 2 (CCR) were combining to achieve more potent 
T-cell activation. However, the powerful signaling mediated 
through the CAR meant that tumors expressing ErbB2 
alone were lysed as efficiently as ErbB2+ MUC-1+ tumor 
cells by dual targeted T-cells. Kloss and colleagues observed 
a similar result in vivo using T-cells expressing a CD19-
specific CAR alongside a CCR targeting prostate-specific 
membrane antigen (PSMA) (12). Whilst the CAR/CCR 
T-cells eradicated CD19+ PSMA+ tumors in vivo, they also 
mediated rejection of CD19+ PSMA− tumors. This effect 
could be remedied by reducing CAR activity below the 
level required to achieve T-cell activation. Consequently, 
a sufficient activation threshold could only be reached by 
simultaneous provision of the signal from the CCR (Figure 
1A). T-cells co-expressing a poorly active CAR targeting 
the prostate stem cell antigen (PSCA) with the PSMA 
CCR resulted in the rejection of PSCA+ PSMA+ tumors, 
but no recognition of tumors expressing either antigen in 
isolation. These data were therefore the first to demonstrate 
an efficiently functioning AND gate in CAR T-cells that 
mediated selective tumor targeting. Similar results have 
since been observed using CAR/CCR targeting mesothelin 
and alpha-folate receptor respectively (13), although the 
higher background against single positive tumors further 
demonstrates the importance of minimizing the activity 
of the CAR. Crucially, these results were achieved using 
physiologically relevant antigen combinations, as PSCA and 
PSMA or mesothelin and alpha-folate receptor are often 
co-expressed in prostate and ovarian cancer respectively, 
but their expression in healthy tissue does not overlap. 
Differences in target antigen expression between species 
and the inability of the CARs to cross-react with murine 
tissue ultimately preclude meaningful toxicity testing from 
being undertaken in these models. Consequently, the 
overall efficacy and stringency of this approach can only be 
truly verified in human trials. 
One potential concern with this approach is whether 
these AND gates will function efficiently against tumor cells 
in which there is an antigenic imbalance. Indeed, whether 
these CAR/CCR T-cells can be efficiently activated by 
tumors expressing low levels of the CCR antigen remains 
to be seen and could represent a potential mechanism 
of immune escape. Consequently, determination of the 
minimal level of CCR activation required to mediate T-cell 
activation would prove beneficial prior to human studies. 
To overcome the potential issue of antigen imbalance 
affecting the function of AND gate CARs, Roybal et al. 
have designed an elegant gating strategy that relies on 
sequential signaling to achieve CAR T-cell activation. To 
achieve this, expression of a potent second generation CAR 
is placed under the control of an inducible promoter that 
is only activated in response to signals mediated from a 
constitutively expressed synthetic receptor, termed synNotch. 
These synNotch receptors use the regulatory core region of 
the wild-type Notch receptor to couple an antigen binding 
domain to an intracellular transcription factor (14). Ligation 
of the target antigen results in proteolytic cleavage of the 
Notch core region and the release of the transcription 
factor from the cell membrane, from where it translocates 
to the nucleus and drives expression of the CAR. Once 
expressed at the cell surface, the CAR is capable of driving 
T-cell activation and cytotoxicity in response to target cells 
expressing the appropriate target antigen (Figure 1B). As 
proof-of-concept for this idea, a synNotch receptor targeting 
green fluorescent protein (GFP) was coupled to the Gal4-
VP64 transcription factor and co-expressed in primary 
human T-cells with a CD19-specific CAR under the control 
of a promoter with the corresponding Gal4-VP64 response 
elements. When co-cultured in the presence of GFP+ K562 
cells, robust CD19 CAR expression was detected at the 
T-cell surface, but no T-cell activation was demonstrated. In 
contrast, co-culture with GFP+ CD19+ K562 cells resulted 
in robust CAR expression and subsequent target cell lysis. A 
similar result was achieved in vivo, whereby mice treated with 
synNotch AND gate T-cells showed complete eradication of 
GFP+ CD19+ tumors. In contrast, no impact on the growth 
of GFP– CD19+ tumor was observed, regardless of whether 
they received synNotch AND gate, or untransduced T-cells. 
Furthermore, in mice bearing GFP– CD19+ and GFP+ 
CD19+ tumors on contralateral flanks, intravenous treatment 
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with synNotch AND gate T-cells mediated the selective 
eradication of the double positive tumors, whilst those 
lacking GFP expression continued to grow unabated.
These results demonstrate that the orthogonal signaling 
platform provided by use of a synNotch receptor can 
mediate selective targeting of tumor cells displaying a specific 
combination of antigens. Furthermore, this design also 
lends itself to the co-expression of multiple, simultaneous, 
signaling pathways that may enable CAR T-cells to make 
informed functional decisions in response to numerous 
environmental cues. However, this approach also appears 
to have two potential complications. Firstly, the use of 
xenogeneic transcriptional activators, such as Gal4, runs 
the risk of making the T-cells immunogenic. Whilst such 
transcription factors could be replaced by those derived from 
humans, this could undermine the principle of this approach 
by mediating cross-talk between other signaling pathways, 
thereby driving antigen-independent transcription of the 
CAR. Secondly, and of greater concern, is the potential 
for T-cells that have been ‘primed’ through the synNotch 
receptor to target healthy cells that are expressing the chosen 
CAR antigen. During their study, Roybal et al. attempted 
Figure 1 Types of logic gate CARs. (A) In healthy cells, the expression of either antigen A or antigen B results in signaling though either a 
suboptimal first generation CAR (scenario i) or the CCR (scenario ii). In isolation, these signals are insufficient to induce T-cell activation (+). 
Expression of both antigens by tumor cells results in activation of both the CAR and the CCR (scenario iii). A combination of both of these 
signals is sufficient to mediate T-cell activation (++), resulting in tumor cell lysis; (B) in the absence of antigen B, the synNotch receptor is 
not triggered, thus preventing transcription of the CAR (scenario i). Triggering of the synNotch receptor by antigen B results in release of 
the TF. The TF translocates to the nucleus and stimulates transcription of the CAR (scenario ii). However, in the absence of antigen A, no 
signaling is induced through the CAR and ultimately no T-cell activation initiated. In tumor cells, the presence of Antigen A and B activates 
the T-cell through the second generation CAR (++), resulting in target cell lysis (scenario iii); (C) in the presence of both antigen A and 
antigen C (healthy cells), signaling though the CAR is inhibited by the iCAR (scenario i). In tumor cells, the absence of antigen C prevents 
iCAR-mediated inhibition of the CAR, resulting in T-cell activation (++) and target cell lysis (scenario ii). CAR, chimeric antigen receptor; 
iCAR, inhibitory CAR; CCR, chimeric co-stimulatory receptor; TF, transcription factor. 
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to address this issue by investigating the ability of synNotch 
AND gate T-cells to migrate to and destroy GFP– CD19+ 
tumors following administration into mice bearing a GFP+ 
CD19– tumor on the contralateral flank. As the growth of the 
CD19+ tumors was not impeded by the synNotch AND gate 
T-cells, they concluded that priming of these T-cells would 
not result in subsequent targeting of cells solely expressing 
CD19+. They attributed this to the relatively rapid decay 
of CAR expression at the T-cell surface in the absence of 
continued synNotch receptor activation (t1/2 = approximately 
8 hours). They concluded that this decay was likely quicker 
than the time taken for the T-cells to migrate to the CD19+ 
tumors. Whilst this data is encouraging, it does not address 
the potential toxicity that may occur when tumor and healthy 
tissue are co-localised. Consequently, experiments in which 
cells expressing either antigen in isolation are mixed, or 
engrafted in close proximity may be more informative of the 
potential of these synNotch AND gates to mediate targeting 
of bystander cells.
Unfortunately, whilst targeting two antigens to improve 
tumor selectivity is the founding principal of the AND 
gate platform, it may also represent the Achilles’ heel of 
this technology. The ability of CAR T-cell therapy to drive 
immune evasion has been powerfully demonstrated by 
the emergence of epitope negative B-ALL cells following 
treatment with CD19 CAR T-cells (15). By increasing 
the number of antigens required to achieve CAR T-cell 
activation, it is logical to hypothesize that this may also 
increases the chance of antigen loss, especially if one of the 
target antigens does not contribute to the transformed state 
of the tumor cells. 
One potential strategy to circumvent this is through the 
use of NOT gates. In contrast to AND gates, NOT gated 
CAR T-cells are activated by binding to a single antigen. 
However, the binding of a second receptor to an alternative 
antigen functions to override the activating signal being 
perpetuated through the CAR in a manner akin to that 
seen in natural killer cells (Figure 1C). Theoretically, this 
inhibitory receptor would be targeted against an antigen 
that is abundantly expressed in healthy tissue but absent in 
tumor cells. To this end, Federov and colleagues developed 
an inhibitory CAR (iCAR), in which a PSMA-specific 
antigen binding domain was coupled to the inhibitory 
intracellular domain from programmed death-1 (PD-1). 
When co-expressed with a CD19-specific CAR, this iCAR 
was able to significantly inhibit CAR T-cell function against 
cells co-expressing PSMA and CD19 (16). In contrast, these 
CAR/iCAR T-cells efficiently lysed CD19+ cells, as the 
lack of PSMA expression meant that no inhibitory signal 
was generated. Both CD19+ and CD19+ PSMA+ tumors 
were efficiently eliminated by T-cells solely expressing the 
CD19 CAR. Crucially, these NOT gated T-cells were able 
to discern between target and non-target cells in a mixed 
population in vitro and in vivo, with selective elimination 
of CD19+ tumor cells achieved in both models. Whilst 
encouraging, a low level of CD19+ PSMA+ tumor targeting 
was observed with the CAR/iCAR T-cells. Further 
optimization of this strategy is thus required to ascertain 
the most potent combination of activating and inhibitory 
signals. Of additional importance is confirmation of the 
functionality of this approach using physiologically relevant 
antigen combinations. Indeed, identifying an appropriate 
target antigen to trigger the iCAR is potentially the biggest 
hurdle facing the continued development of NOT gated 
CAR T-cells.
Overall, these studies demonstrate that engrafting 
primary human T-cells with Boolean logic gate CARs 
enables them to respond to multiple input signals, thereby 
allowing targeting of antigenic patterns. Achieving potent 
tumor eradication in the absence of toxicity is the ultimate 
goal of adoptive T-cell therapy. Whether this can be 
successfully achieved will ultimately be confirmed in human 
trials, but the use of logic gates suggests that such an 
outcome is possible. 
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